Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Guido Hartmann

Patrizio Mattei

Johannes Aebi

Luke Green

Hans Peter Maerki

Alfred Binggeli

Fabienne Ricklin

Olivier Roche

Olaf Mundigl

Stefan Dengl

Joerg Moelleken

Peter Michael Huelsmann

Christian Gassner

Guy Georges

Joerg Thomas Regula

Sabine Imhof-Jung

Hubert Kettenberger

Roland Beckmann

Barbara Weiser

Sabine Gruener

Sebastian Breuer

Wolfgang Haap

David Banner

Ralf Schumacher

Michael Molhoj

Kristian Hobolt Jensen

Joerg Benz

Jean-Michel Adam

Stefan Lorenz

Marc Bedoucha

Bernd Kuhn

Hans Hilpert

Uwe Grether

Wolfgang Schaefer

Jens-Uwe Peters

Jean-Marc Plancher

Simona Maria Ceccarelli

Holger Kuehne

Thomas Luebbers

Tilman Schlothauer

Harald Mauser

Matthias Rueth

Christian Schantz

Sebastian Fenn

Delphine Gaufreteau

Lilli Anselm

Jean-Baptiste Blanc

Beat Spinnler

Ruben Alvarez Sanchez

Rubén Alvarez Sánchez

Peter Hartman

Janina Speck

Kristian Hobolt-Jensen

Christoph Ullmer

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.

Antibody that binds to VEGF-A and ANG2 and methods of use

Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Human FcRn-binding modified antibodies and methods of use

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.

Anti-IL-1beta antibodies

Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.

Anti-PDGF-B antibodies and methods of use

The invention relates to a compound of formula (I) wherein A, B, D and Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Cyclic amides

The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R, R, R, R, R, R, R, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Bicyclic compounds

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R, R, R, R, R, R, R, R, R, R, and Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

Heterocyclyl compounds

The invention is concerned with novel heteroaryl carboxamide derivatives of formula (I), wherein m, X, Y, R, R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Heteroaryl carboxamide derivatives

The invention relates to a compound of formula (I) wherein A, R-Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Proline derivatives

The invention is concerned with novel biaryl derivatives of formula (I), wherein m, R, R, R, X, Xand Xare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Biaryl derivatives

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, Y, Y, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Growing community of inventors

Loerrach, Germany

Guido Hartmann